Seres Therapeutics (NASDAQ:MCRB – Get Free Report) and BioLineRx (NASDAQ:BLRX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings.
Profitability
This table compares Seres Therapeutics and BioLineRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Seres Therapeutics | -1,192.94% | -114.82% | -34.15% |
| BioLineRx | -502.08% | -34.80% | -18.27% |
Risk and Volatility
Seres Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.
Insider and Institutional Ownership
59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Seres Therapeutics and BioLineRx”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Seres Therapeutics | $790,000.00 | 29.39 | $5.70 million | ($2.43) | -0.95 |
| BioLineRx | $1.18 million | 9.03 | -$1.17 million | ($1.69) | -1.27 |
Seres Therapeutics has higher earnings, but lower revenue than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and target prices for Seres Therapeutics and BioLineRx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Seres Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
Seres Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 635.93%. Given Seres Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Seres Therapeutics is more favorable than BioLineRx.
Summary
Seres Therapeutics beats BioLineRx on 7 of the 13 factors compared between the two stocks.
About Seres Therapeutics
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
